Resources

CAR T-Cell Therapy Perceptions

Subsequent to a report of a chromosomal abnormality in CAR T-cells in a patient treated in an allogeneic CAR T-cell therapy clinical trial, the FDA has placed a hold on allogeneic CAR T-cell therapy clinical trials being conducted by that company.

InCrowd wanted to understand how this FDA action affected oncologists’ and hematologists’ perceptions of CAR T-cell therapy in both the allogeneic and autologous spaces and gene therapy in general.

Download the latest InCrowd Instant Insights report to learn how 76 US oncologists, hematologists, and hematology-oncologists felt about the future of CAR T-Cell therapy and the impact of FDA actions on their perceptions of gene therapy. 

Please fill out the form below to access this content

Name(Required)
This field is for validation purposes and should be left unchanged.

Related Resources

Instant Insights – Weight Loss Drugs

Instant Insights – Weight Loss Drugs

Prescriber Perspectives on Weight Loss Drugs in 2023 Examine how healthcare professionals (HCPs) view and prescribe weight loss drugs currently on the market in our new Instant Insights report. Fielded in a single day, this report includes responses from 100 qualified...

read more
Post-ASCO Excitement Report

Post-ASCO Excitement Report

Physician Perspectives on the 2023 ASCO Annual Meeting Curious what doctors thought about ASCO? Nearly 100 oncologists and hematologist oncologists shared with us the findings and developments they were most excited about. Check-out our 2023 Post-ASCO report to...

read more
2023 Q1 – NSCLC Essentials Readout

2023 Q1 – NSCLC Essentials Readout

Adoption of Newly-Approved 1L mNSCLC Regimens Driven by Promotional Activities Promotion plays a major role in the successful launch of a new pharmaceutical product. Companies must develop a marketing strategy that effectively communicates the benefits of the therapy...

read more